HeartSciences Inc. has entered into an Equity Distribution Agreement with Maxim Group LLC to sell up to $50,000,000 of its common stock. The agreement, dated November 18, 2026, allows the company to offer and sell shares from time to time through an "at the market" offering, as defined under Securities and Exchange Commission Rule 415(a)(4).

The shares will be issued pursuant to a shelf registration statement on Form S-3, which was declared effective by the SEC on November 17, 2026. A prospectus supplement dated November 19, 2026, will be filed with the SEC to accompany the offering. Under the terms of the agreement, Maxim Group will act as sales agent and is required to use commercially reasonable efforts to sell the shares based on the company's instructions, including any price, time, or size limits specified by HeartSciences.

HeartSciences will pay Maxim Group a commission of 2.5% on gross sales proceeds for so long as the company remains subject to certain limitations under Form S-3, and 2.0% thereafter. The company will also reimburse Maxim Group for legal fees and expenses related to the agreement, up to $15,000, plus $5,000 per Bringdown Date. Maxim Group is not obligated to purchase any shares on a principal basis.

The agreement may be terminated by either party upon notice. Additionally, the filing notes that HeartSciences is currently involved in a proposed merger with Fortitude Mining Holdings, Inc., and is soliciting proxies from shareholders regarding this transaction.